RxDoctor Payments Data

Julie Bichelmeyer

Nurse Practitioner · Overland Park, KSNPI 1578100509

Payments from drug & device makers

$3,698in general payments, 2019–2025

Across 198 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$605
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$544
  • E.r. Squibb & Sons, L.L.C.$411
  • Johnson & Johnson$394
  • Novartis$306
  • Novo Nordisk$258
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,698100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,698 in reported general payments places this provider in the 90th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$8,918
Medicare patients
72
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$253,806
XareltoRivaroxaban149$158,236
JardianceEmpagliflozin38$52,225
Repatha SureclickEvolocumab49$51,701
EntrestoSacubitril/Valsartan47$50,770
Praluent PenAlirocumab14$9,961
Atorvastatin Calcium560$5,681
Dabigatran EtexilateDabigatran Etexilate Mesylate12$5,065
Ezetimibe221$4,360
Flecainide Acetate70$4,258
Losartan Potassium334$3,949
Rosuvastatin Calcium347$3,730
Metoprolol Succinate291$3,174
Potassium Chloride118$3,060
Ranolazine ErRanolazine21$2,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$178$253,806231 claims
Johnson & JohnsonXarelto$394$158,236149 claims
Boehringer IngelheimJardiance$605$52,22538 claims
NovartisEntresto$306$50,77047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →